FDA Approves Argenx’s VYVGART Hytrulo To Treat CIDP
The US Food and Drug Administration (FDA) has approved Argenx’s VYVGART Hytrulo to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP). Intended for use as a once-weekly subcutaneous injection over 30 to 90 seconds, VYVGART Hytrulo is the first and only neonatal Fc receptor (FcRn) …